Farabi Pharmaceutical (XTEH:DFRB1) Valuation Rank


What is Farabi Pharmaceutical Valuation Rank?

The Valuation Rank measures the current valuation of a business relative to other companies in the same industry and its own historical valuation. The companies are split in equal numbers and then ranked from 1 to 10, with 10 as the most undervalued and 1 as the most overvalued.

  1. Three factors:
    • Absolute valuation (medpsvalue) relative to current stock price, rank among all companies
    • Historical valuation over the past 10 years. Rank pe, ps, pocf, ev2ebit over their own historical values
    • Industry relative valuation
  2. Companies without enough data is not ranked
  3. Companies with negative earnings are ranked lower

These three factors are used to calculate the value score for every eligible company, with values from 1 to 10. The final ranked companies are split in equal numbers and ranked from 1 to 10, with 10 as the most undervalued, and 1 as the most overvalued. The numbers of companies in each rank are the same.

Farabi Pharmaceutical Valuation Rank Related Terms

Farabi Pharmaceutical Business Description

Address South Kheradmand, No. 45, First Floor, Tehran, IRN, 1584853114
Farabi Pharmaceutical is a pharmaceutical company based in Iran. It produces various oral antibiotic-related and non-antibiotic products and dietary supplements. The company develops anti-migraine, antivirals, cholesterol, diabetic, cardiovascular, gastrointestinal, neuroleptics, anti-prostatic and anti-inflammatory and pain release drugs. It offers products in the form of tablet, capsule and suspensions which include Amoxicillin, Cefixime, Azithromycin, Ciprofloxacin, Nitroglycerin, Repaglinide, Orlistat, Domperidone, among others.